By LAURAN NEERGAARD (AP Medical Writer)
WASHINGTON — Another experimental Alzheimer’s drug can modestly gradual sufferers’ inevitable worsening — by about 4 to seven months, researchers reported Monday.
Eli Lilly and Co. is looking for Food and Drug Administration approval of donanemab. If cleared, it could be solely the second Alzheimer’s therapy convincingly proven to delay the mind-robbing illness — after the not too long ago accredited Leqembi from Japanese drugmaker Eisai.
“Finally there’s some hope, right, that we can talk about,” Lilly’s Dr. John Sims informed reporters Monday on the Alzheimer’s Association International Conference in Amsterdam.
“We don’t cure the disease,” he stated. “Diabetes doesn’t have a cure either — it doesn’t mean you can’t have very meaningful treatments for patients.”
Lilly introduced in May that donanemab appeared to work, however on Monday the total outcomes of a examine of 1,700 sufferers was revealed by the Journal of the American Medical Association and offered on the Alzheimer’s convention.
Both donanemab and Leqembi are lab-made antibodies, administered by IV, that concentrate on one Alzheimer’s offender, sticky amyloid buildup within the mind. And each medicine include a severe security concern — mind swelling or bleeding that within the Lilly examine was linked to 3 deaths.
Scientists say whereas these medicine could mark a brand new period in Alzheimer’s remedy, big questions stay about which sufferers ought to attempt them and the way a lot profit they’ll actually discover.
“The modest benefits would likely not be questioned by patients, clinicians or payers if amyloid antibodies were low risk, inexpensive and simple to administer. However, they are none of these,” Dr. Eric Widera of the University of California, San Francisco, wrote in a JAMA editorial accompanying Lilly’s new information.
Lilly’s examine enrolled individuals ages 60 to 85 who had been in early levels of Alzheimer’s. Half obtained once-a-month infusions of donanemab and half dummy infusions for 18 months.
The examine had just a few twists. Patients had been switched to dummy infusions if sufficient amyloid cleared out — one thing that occurred to about half inside a yr. And as a result of amyloid alone doesn’t trigger Alzheimer’s, researchers additionally tracked ranges of one other offender within the mind — irregular tau. More tau alerts extra superior illness.
The outcomes: Both teams declined through the 18-month examine however total these given donanemab worsened about 22% extra slowly. Some sufferers fared higher — these with low to medium tau ranges noticed a 35% slower decline, reflecting that the drug seems to work higher in earlier levels of the illness.
How a lot distinction does that make? It means donanemab slowed sufferers’ worsening by about 4 to seven months, the JAMA report concluded.
Another means of measuring: Among the donanemab recipients with decrease tau ranges, 47% had been thought-about secure a yr into the examine in contrast with 29% of those that obtained the dummy model.
The most important security concern is mind swelling or bleeding, which frequently causes no signs however typically may be severe, even deadly. About 1 / 4 of donanemab recipients confirmed proof of that swelling, and about 20% had microbleeds.
Scientists already know that sufferers getting any amyloid-targeted remedy want repeat mind scans to verify for these unwanted effects — a expensive and time-consuming hurdle.
Widera famous that the potential for stopping donanemab therapy at the very least quickly in individuals who reply effectively would assist restrict a few of these challenges. For comparability, Leqembi is given by IV each two weeks and researchers didn’t check an analogous stoppage.
It’s too quickly to know if some sufferers would possibly have to resume donanemab, stated Lilly’s Dr. Mark Mintun. But the amyloid “doesn’t come back with any sort of vengeance,” he stated, speculating which may take a number of years.
Another concern: More than 90% of the examine’s contributors had been white, leaving little information about how different populations would possibly reply, Alzheimer’s specialist Jennifer Manly of Columbia University wrote in JAMA.
Scientists have lengthy tried and did not gradual Alzheimer’s with amyloid-targeting medicine — and the FDA’s contentious 2021 conditional approval of a drug named Aduhelm quickly fizzled amid lack of proof that it actually labored. The approval of Leqembi and promising information for donanemab have reignited curiosity in attacking amyloid buildup.
But Mintun acknowledged further approaches are wanted, saying Lilly expects outcomes of a late-stage examine of a tau-fighting drug subsequent yr.
___
The Associated Press Health and Science Department receives help from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely chargeable for all content material.
Source: www.bostonherald.com”